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Abstract
Background: Intradialytic hypotension may adversely affect the outcome of chronic hemodialysis. Therapeutic
albumin has powerful anti-oxidant and anti-inflammatory properties. We have recently shown that systematic
colloid infusion during hemodialysis sessions improves hemodynamic parameters in most dialysis hypotension-
prone patients unresponsive to usual of preventive measures.
We postulated that frequent hypotensive episodes may lead to a noxious inflammatory response mediated by
oxidative stress induced by ischemia-reperfusion. The aim of this study was therefore to analyze the effect of 20%
albumin and 4% gelatin infusions on oxidative stress and microinflammatory status in hypotension-prone patients
unresponsive to usual preventive measures.
Methods: Prospective cross-over study (lasting 20 weeks) of routine infusion of 200 ml of 20% albumin versus 200
ml of 4% gelatin in 10 patients with refractory intradialytic hypotension. We analyzed the effect of 20% albumin
and 4% gelatin on microinflammatory status, oxidative stress, serum nitrite and nitrate levels by analysis of variance.
Results: A significant decrease in serum ceruloplasmin and serum C3 was observed during the albumin period (p
< 0.05, repeated measure ANOVA). A significant decrease in serum hydrogen peroxide was seen during albumin
and gelatin administration (p < 0.01, repeated measure ANOVA) and a very large decrease in serum lipid peroxides
was observed during the albumin period only (p < 0.01, Friedman test). Serum lactoferrin, serum proinflammatory
cytokines and serum nitrite and nitrate levels remained stable during the different periods of this pilot trial.
Conclusions: We conclude that the improvement in microinflammatory status observed during colloid infusion in
hypotension-prone dialysis patients may be related to a decrease in ischemia-reperfusion of noble organs, together
with a specific reduction in oxidative stress by albumin.
Trial registration: ISRCTN 20957055
Keywords: dialytic hypotension, 4% gelatin, 20% hyperoncotic albumin, microinflammatory status, oxidative stress
Background
Intradialytic hypotension is the most common complica-
tion of hemodialysis, affecting up to 33% of patients. It
interferes with patients’ well being and prevents ade-
quate dialysis and fluid removal [1-3]. Intradialytic hypo-
tension has a negative impact on health-related quality
of life and reduces patients’ life expectancy, favoring
underdialysis and increasing the risk of ischemia or
infarction of noble organs such as the heart, brain and
bowel [2-4].
Recent studies have shown that human albumin can
be safely used in intensive care patients [5] and exerts
powerful anti-oxidant properties [6]. It may also better
restore volemia and arterial pressure than saline deriva-
tives in dialytic hypotension-prone patients, especially
those with cardiovascular disease [7,8]. We recently con-
ducted a 20-week a single-blind prospective cross-over
pilot trial of systematic infusion of 20% albumin as com-
pared to 4% gelatin in 10 hypotension-prone patients on
long-term bicarbonate hemodialysis and unresponsive to
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profiling. We observed a potential benefit of systematic
colloid infusion, especially 20% albumin, in this subset
of patients [9]. We postulated that frequent episodes of
hypotension may induce a noxious inflammatory
response mediated by oxidative stress induced by ische-
mia-reperfusion.
The aim of the present study was to analyze the effect
of systematic infusion of 20% albumin and 4% gelatin
on micro-inflammatory status, oxidative stress, serum
nitrates and nitrites in these hypotension-prone patients
unresponsive to usual preventive measures.
Methods
Patients and dialysis
Ten patients (6 women, 4 men) undergoing chronic inter-
mittent bipuncture bicarbonate hemodialysis three times
per week on a Cimino-Brescia fistula were included.
All the patients gave their written informed consent to
the study. Their median age was 71.5 years (range: 45-
91 years) and the median time spent on hemodialysis
was 4 years (range: 1-9 years). The main characteristics
of the patients are summarized in Table 1.
All the patients experienced a hypotensive episode
more than once a week, as defined by a systolic pressure
(SBP) < 100 mmHg or a fall in systolic pressure > 30
mmHg associated with symptoms of hypotension. All
the patients were at their optimal dry weight, as shown
by normovolemia on echography of the inferior vena
cava and echocardiography after a dialysis session or the
following morning after an evening dialysis session
[10,11]. Hemodialysis was performed using an Integra
module (Hospal, Lyon, France), with ultrapure dialysate
(bacterial content: < 0.1 CFU/ml and endotoxin content
< 0.03 U/ml; dialysis water supply from Gambro,
Colombes, France); the blood flow rate was 250-300 ml/
min and the dialysate flow rate was 500 ml/min.
Dialysate temperature, dialysate composition (505 A
from Fresenius, Fresnes, France) and the sodium and
ultrafiltration profiles did not differ between the four
treatment periods. Details on the patients’ clinical condi-
tions are provided in a recently published article [9].
Study protocol
Trial registration
T h i st r i a lr e c e i v e da p p r o v a l( n ° 0 2 - 0 1 7 )f r o mt h ee t h i c s
committee of Henri Mondor University Hospital and
was registered with the French Agency for Drugs and
Health Devices AFSSAPS (n° 021059) and with ISRCTN
register (reference 20957055).
Table 1 Characteristics of the patients
n° Age
(year)
Gender Duration of
dialysis
(years)
Cause of renal
failure
Dialysis membrane Modality
of
dialysis
Risks factors for dialysis hypotension
1 45 F 9 SLE Polysufone
(ARYLANE H4 -
Hospal)
4h×3 /
Week
Long duration of dialysis (9 years), SLE still active treated
by steroïds and ciclosporin - Diastolic dysfunction
2 91 F 2 Atherosclerotic
nephropathy
Diacetate
(DICEA130-Baxter)
3h×3 /
Week
Very old age, severe ischemic cardiopathy - Diastolic
dysfunction
3 67 F 6 Interstitial
nephrotoxic
nephritis
(Ciclosporin)
PMMA (BKF16-Toray) 4 h × 3/
Week
Cardiac graft for ten years-Diastolic dysfunction
4 87 M 2 Atherosclerotic
nephropathy
Diacetate (DICEA
150-Baxter)
3h×3 /
Week
Very old age, severe ischemic cardiopathy-Diastolic
dysfunction
5 76 M 3 Diabetes melitus
type II
Triacetate
(TRICEA210-Baxter)
4h×3 /
Week
Old age, diabetes, pace-maker, panhypotuitarism -
Diastolic dvsfunction
6 84 F 3 Renal and urologic
tuberculosis
Diacetate (DICEA
130-Baxter)
3 h30 ×
3/Week
Very old age, severe ischemic and valvular cardiopathy -
Diastolic dysfunction
7 71 M 5 Atherosclerotic
nephropathy
Chemically modified
Acetate (SMC 170 -
Bellco)
4×3h /
Week
Old age, severe ischemic cardiopathy-Diastolic
dysfunction
8 72 M 1 Myeloma Triacetate
(TRICEA210-Baxter)
3 h30 ×
3/Week
Old age, severe ischemic cardiopathy, arythmia
secondary to atrial fibrillation - chemotherapy for
myeloma - Diastolic dysfunction
9 70 F 7 Analgesic
nephropathy
Diacetate (DICEA
130-Baxter)
4h×3 /
Week
Old age, long duration of dialysis (7 years), arythmia
secondary to atrial fibrillation-Diastolic dysfunction
10 50 F 6 Autosomic
dominant polycystic
kidney disease
PAN (NEPHRAL 300-
Hospal)
4h×3 /
Week
Binephrectomy - Diastolic dysfunction
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Study design
This was a randomized four-period cross-over study
lasting 20 weeks. Patients were randomized to one of
two treatment sequences (sequence 1 or sequence 2:
Figure 1: see details of study protocol in reference 9).
Briefly, for sequence 1, after 35 days without treat-
ment, the participants (n = 5) received an infusion of
200 ml of 20% albumin (Vialebex, LFB, Les Ulis, France)
(from day 0 to day 35), followed by a washout period of
35 days, on 4% gelatin infusion (Gelofusin, Braun medi-
cal, Boulogne, France). During the last period from day
70 to day 105, the participants received systematic infu-
sions of 200 ml of 4% gelatin.
For sequence 2, the participants (n = 5) received from
day 0 to day 35 a systematic infusion of 200 ml 4% gela-
tin, followed by a washout period from day 35 to day 70
on 4% gelatin infusion; during the last period the parti-
cipants received systematic infusions of 200 ml of 20%
albumin.
Systematic infusion of 200 ml of 4% gelatin was
required during the wash-out period by the ethics com-
mittee, to avoid noxious consequences of dialytic hypo-
tension; the aim of this wash-out period was to avoid a
carry-over effect of 20% albumin.
Outcome measures
The primary outcome measure was arterial pressure reg-
ulation and secondary outcome measures were nutri-
tional status, ultrafiltration rate and dialysis quality, as
recently reported [9]. Other secondary outcome mea-
sures, which included the effect of 20% albumin and 4%
gelatin on microinflammatory status, oxidative stress,
and serum nitrate and nitrite levels, are the subject of
this study.
Study of microinflammatory status, oxidative stress,
and serum nitrite and nitrate levels Serum and plasma
samples were prepared before and at the end of the last
dialysis session in each of the four protocol periods. We
analyzed micro-inflammatory status by measuring C-
reactive protein, C3, haptoglobin and ceruloplasmin by
nephelemetry (Minineph kits, The Binding Site Ltd;
Saint-Egrève, France). We measured serum lactoferrin
as a marker of polymorphonuclear neutrophil activation
during dialysis sessions by using a home-made ELISA
with rabbit anti-human lactoferrin and purified human
lactoferrin purchased respectively from Biodesign Inter-
national (Saco, USA) and Sigma-Aldrich (Saint Quentin
Fallavier, France). We measured serum proinflammatory
cytokines (IL1 beta, IL6, IL8, TNF alpha) as markers of
monocyte activation during dialysis sessions, after blood
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Figure 1 Study Protocol.
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Chromogenix; Vienna, Austria), using ELISA kits (R and
D systems; Lille, France). We analyzed oxidative stress
by measuring circulating hydrogen peroxide and total
lipid peroxides with colorimetric assays (Hydrogen Per-
oxide Kit, Assay Designs, Inc; Ann Arbor, USA and Per
Ox Assay, Immunodiagnostik, Orange Medical, Brussels,
Belgium). We measured nitrotyrosine, a stable endpro-
duct of peroxynitrite oxidation, as a marker of NO-
dependent damage in vivo, by using an ELISA method
(HyCult biotechnology, Tebu-bio; Le Perray en Yvelines,
France). We also analyzed the total antioxidant power of
plasma after uric acid depletion (using rasburicase, 2.5
μL/100 μL of serum for one hour at 30°C: Fasturtec 1.5
mg/ml, Sanofi-Synthelabo, Paris France) by using a col-
orimetric assay based on the evaluation of Cu
+ derived
from Cu
++ by the combined action of all antioxidants in
the sample (Oxford Biomedical Research, Oxford, UK).
As NO has been implicated in the pathophysiology of
dialytic hypotension, we measured serum nitrite and
nitrate levels by spectrophotometry, based on the Griess
reaction after extensive centrifugation of the samples at
4°C on Biomax-PB Ultrafree-MC centrifugal filter units
with ultrafiltration membranes with a cut-off of 10 000
NMWL (Millipore, Saint-Quentin en Yvelines, France)
and enzymatic conversion of nitrate to nitrite by nitrate
reductase (Nitric oxide (NO2
-/NO3
-) assay (R and D
systems; Lille, France).
Statistical analyses We analyzed the effect of albumin
and gelatin infusions on arterial pressure regulation (pri-
mary outcome measure), i.e. SBP (systolic blood pres-
sure) and DBP (diastolic blood pressure), and the
number of hypotensive episodes (defined as SBP < 100
mmHg, regardless of symptoms) and changes in the
ultrafiltration rate and interdialytic weight gain (post-
hoc analyses) in each individual (in both regular and
additional dialysis sessions) by the n-of-1 trial methodol-
ogy implemented with the Wilcoxon test. We also ana-
lyzed the effect of the colloids on dialysis quality (single
pool Kt/V, ionic dialysance 30 minutes before the end
of the dialysis session, decrease in relative blood volume)
and nutritional parameters (serum albumin and prealbu-
min) by analysis of variance (see details in reference 9).
Changes in microinflammatory status, oxidative stress,
serum cytokine, lactoferrin, nitrate and nitrite levels
during the four periods of the protocol were analyzed
with either parametric or non parametric analysis of var-
iance followed by post-tests depending on the normality
of the distribution (in the Kolmogorow-Smirnov test)
[12] using Prism 4 software (Graphpad, San Diego,
USA). P values < 0.05 were considered significant [12].
Values are expressed as means ± SD or medians and
ranges, depending on the normality of the distribution
[12].
Results
Hemodynamics, dialysis quality and nutritional
parameters
Statistical analysis of individual data by the n-of-1 metho-
dology showed that 20% albumin increased systolic blood
pressure (SBP) in 6 patients (p < 0.05, Wilcoxon test)
whereas 4% gelatin improved SBP in only 3 patients (p <
0.05, Wilcoxon test). Albumin infusions increased diasto-
lic blood pressure (DBP) in 4 patients (p < 0.05, Wil-
coxon test), whereas gelatin improved DBP in only 1
patient (p < 0.05, Wilcoxon test). Weight gain between
dialysis sessions was generally similar during the periods
in most patients. An increase in the ultrafiltration rate
was observed in 5 of the 6 patients whose blood pressure
was improved by colloids (p < 0.005, Wilcoxon test) les-
sening the need for additional dialysis sessions and redu-
cing the difference between the target dry weight and
weight measured at the end of the dialysis sessions. Kt/V
and the fall in relative blood volume remained stable dur-
ing the study, whereas ionic dialysance at the end of the
dialysis sessions was improved only by albumin infusion
(p < 0.05, repeated measures ANOVA). These results are
extensively analyzed in reference 9.
Microinflammatory status
C-reactive protein and haptoglobin levels did not differ
between the four periods (p > 0.05 repeated measures
ANOVA)(Table 2), whereas serum C3 and ceruloplas-
min levels were significantly reduced during the albumin
period (p < 0.05 non parametric ANOVA, Friedman test
followed by Dunn’s post test)(Figure 2).
Table 2 Inflammatory parameters during albumin and gelatin infusions
Parameter Before
treatment
Albumin infusion
period
Wah-Out
period
Gelatin infusion
period
Statistical analyses
CRP(mg/l) 7.12 ± 8.01 9.25 ± 11.02 6.46 ± 7.10 4.78 ± 4.70 p > 0.05 at the repeated measures
ANOVA
Ceruloplasmin
(g/l)
0.22 [0.14 - 0.34] 0.19 [0.13-0.34] 0.23 [0.16 - 0.32] 0.23 [0.16-0.33] p < 0.05 at the Friedman test
C3 (g/l) 0.97 [0.72-1.59] 0.78 [0.61-1.29] 0.96 [0.71-1.40] 0.96 [0.69-1.39] p < 0.05 at the Friedman test
Haptoglobin
(g/l)
1.35 ± 0.41 1.25 ± 0.50 1.22 ± 0.43 1.31 ± 0.41 p > 0.05 at the repeated mesures
ANOVA
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Plasma total antioxidant power did not differ between the
four periods (p > 0.05 repeated measures ANOVA)(Table
3). Serum hydrogen peroxide values differed between the
four periods (Table 3 and figure 3) (p < 0.01 repeated mea-
sures ANOVA) and were significantly lowered during the
albumin period, wash-out period and gelatin period (p <
0.01 Dunnett’s multiple comparisons test)(Figure 3). Serum
lipid peroxides were strongly and significantly reduced only
during the albumin period (p < 0.01 non parametric
ANOVA Friedman test followed by Dunn’s post-test)
(Table 3 and figure 4). Nitrotyrosine was undetectable at
the beginning of the dialysis sessions during the four peri-
ods (data not shown). Serum lactoferrin levels before and
after dialysis sessions did not differ between the four peri-
ods (p > 0.05 repeated measures ANOVA)(Table 3).
Serum cytokines
IL-1 beta was undetectable both at the beginning and
end of the dialysis sessions during each period of the
protocol (data not shown). Serum levels of the proin-
flammatory cytokines IL6, IL8 and TNF alpha did not
differ between the four periods of the protocol at the
beginning or end of the dialysis sessions (p > 0.05
repeated measures ANOVA)(Table 3).
Serum nitrite and nitrate levels
The sum of serum nitrite and nitrate levels did not dif-
fer between the four periods of the protocol at the
beginning or end of the dialysis sessions (p > 0.05
repeated measures ANOVA)(Table 3).
Discussion
We recently showed in a pilot single-blind cross-over
study, using n-of-1 trial methodology, that systematic
infusion of 20% albumin or 4% gelatin during hemodia-
lysis sessions in hypotension-prone patients unrespon-
sive to preventive measures improves hemodynamic
parameters (systolic and diastolic blood pressure),
increases the ultrafiltration rate and reduces the number
 
Figure 2 Concentration of serum ceruloplasmin (g/l) in the whole group (n = 10).
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lized medication effectiveness tests, are the only way of
resolving clinical uncertainty about whether expensive
new treatments are truly effective for particular patients.
T w op r o v i s o sm u s tb em e t :f i r s t ,t h eh e a l t hp r o b l e m
must be a chronic condition in which the outcome mea-
sure can be palliated but not removed; second, the effect
of treatment should be quantifiable [13,14]. We used the
n-of-1 methodology because, in a chronic illness such as
renal failure requiring chronic hemodialysis, it can pro-
vide an objective basis for identifying treatment out-
comes more subtle than death or survival for an
individual patient with a rare condition such as refrac-
tory dialysis-related hypotension. Moreover, in the case
of a new and expensive therapy such as 20% albumin
(200 ml of 20% albumin costs 80 euros compared to 4
euros for 4% gelatin), n-of-1 trials can furnish powerful
evidence for provision on an individual basis, allaying
managerial and medical fears as to the cost of frequently
ineffective therapies being applied to an expanding at-
risk population [13,14].
In this complementary study, we now show that sys-
tematic infusions of 20% albumin and 4% gelatin in this
subset of hemodialysis patients also improve the micro-
inflammatory state and reduce the abnormal oxidative
stress. Data on the association between inflammatory
status and dialysis hypotension are scarce [15]. Tomita
and coworkers compared nine patients with a history of
intradialytic hypotension with eight patients without dia-
lysis-associated hypotension and found a correlation
between the levels of CRP and IL6 and the maximum
percent change in mean arterial pressure over multiple
dialysis sessions, suggesting that dialysis hypotension
may trigger inflammation [15]. This is consistent with
Bergamini et al, who found significant TNF-alpha
release during hypotensive episodes [16].
In this pilot study, C3 and ceruloplasmin were signifi-
cantly lowered during the albumin period but not dur-
ing the gelatin period. This is consistent with recent
studies using experimental models of hemorrhagic
shock, which indicated that the type of resuscitation
fluid greatly influences proinflammatory responses and
especially neutrophil activation and nuclear factor-
Kappa B gene transcription; albumin was found to be
the least proinflammatory fluid [17,18]. Our patients’
use of ultrapure dialysate may explain the low levels of
CRP and proinflammatory cytokines (IL6, IL8 and TNF
alpha), levels of which have been shown to be greatly
influenced by the type of dialysate: indeed, standard dia-
lysate containing endotoxin, but not ultrapure dialysate,
has been shown to be a potent inducer of these media-
tors [19]. The systemic use of cool dialysate, together
Table 3 Oxidative stress, serum cytokines, serum nitrites and nitrates during albumin and gelatin infusions
Parameter Before
treatment
Albumin
infusion period
Wah-Out
period
Gelatin
infusion period
Statistical analyses
Plasma total anti-oxydant power (copper reducing
equivalent microM)
0.23 ± 0.08 0.26 ± 0.11 0.27 ± 0.13 0.22 ± 0.11 p > 0.05 at the repeated
measures ANOVA
Hydrogen peroxyde μg/ml 29.97 ± 7.3 10.87 ± 1.9 14.57 ± 2.5 11.19 ± 2.4 p < 0.001 at the repeated
measures ANOVA
Lipid peroxides (H202 equivalent) μM/1 50
[13.84-189.5]
7 [7-209.4] 37.30
[7-305]
38.20
[7.82-298.7]
p < 0.005 at the Friedman
test
Lactoferrin at the beginning of the dialysis session
(ng/ml)
245.7 ± 154 199.3 ± 133 154 ±
36.98
153.7 ± 29.79 p > 0.05 at the repeated
measures ANOVA
Lactoferrin at the end of the dialysis session (ng/ml) 159.7 ±
40.52
144.5 ± 48 152.8 ±
31.42
154.9 ± 74.31 p > 0.05 at the repeated
measures ANOVA
IL6 at the beginning of the dialysis session (pg/ml) 5.55 ± 8.19 2.44 ± 2.82 2.19 ± 2.87 1.74 ± 2.51 p > 0.05 at the repeated
measures ANOVA
IL6 at the end of the dialysis session (pg/ml) 6.88 ± 7.56 6 ± 3.98 4.26 ± 2.19 5 ± 3.4 p > 0.05 at the repeated
measures ANOVA
IL8 at the beginning of the dialysis session (pg/ml) 32.77 ±
43.79
21 ± 9.89 24 ± 18 19.83 ± 13.89 p > 0.05 at the Friedman
test
TNF a at the beginning of the dialysis session pg/
ml
9.85 ± 10.82 9.13 ± 5.87 8.04 ±
10.22
4.72 ± 3.59 p > 0.05 at the repeated
measures ANOVA
TNF a at the end of the dialysis session pg/ml 8.33 ± 7.17 7.59 ± 4.67 5.40 ± 2.82 4.51 ± 2.96 p > 0.05 at the repeated
measures ANOVA
Serum nitrates + nitrites at the beginning of the
dialysis session (μmol/1)
49 ± 24.90 50.35 ± 30.87 53.66 ± 26 55.35 ± 28.42 p > 0.05 at the repeated
measures ANOVA
Serum nitrates + nitrites at the end of the dialysis
session (μmol/I)
45.34 ±
27.16
48.58 ± 17.78 47.27 ± 20 53.70 ± 34.48 p > 0.05 at the repeated
measures ANOVA
The values are given either as mean ± SD in case of gaussian distribution or as medium [range] in case of non parametric distribution
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infusion may also have contributed to these low levels
of CRP and pro-inflammatory cytokines [9].
Conversely, ex-vivo data suggest that uremia may
increase vascular permeability [20], which may rise
acutely during dialysis-associated hypotension via the
release of mediators such as adenosine, aimed at preser-
ving perfusion of noble organs [21]; in this setting, albu-
min may itself influence vascular integrity by binding to
the interstitial matrix and subendothelium and by alter-
ing the permeability of these layers to large molecules
and solutes; these effects may be mediated by the bind-
ing of arachidonic acid to albumin and by polynitroxy-
lated albumin, which inhibits xanthine-oxidase-mediated
adhesion of human neutrophils to endothelial cells [22].
We found that serum hydrogen peroxide levels were
significantly lowered during both the albumin and the
gelatin periods, suggesting that the improvement in
hemodynamic parameters by colloids reduces oxidative
stress related to the ischemia-reperfusion of noble
organs that occurs during dialytic hypotension [23]. In
addition to classical ischemia-reperfusion mechanism, by
analogy with heart failure, entry of bacterial endotoxin
during dialysis sessions might result from intermittent
underperfusion of the intestine during dialysis-associated
hypotension, leading to cardiac stunning and oxidative
stress [24-26]. Thus, colloids may improve both systemic
and intestinal perfusion and reduce gut ischemia
[24-26]. These data also strongly suggest that dialytic
hypotension may contribute in various ways to the over-
production of reactive oxygen species seen in end-stage
renal failure patients, a multifactorial process mainly
related to uremia itself, hemoincompatibility of the dia-
lysis system and trace amounts of endotoxin in the dia-
lysate [27].
In this pilot study, serum lipid peroxide levels were
significantly reduced only during the albumin period.
This is consistent with data showing that human
serum albumin and bovine serum albumin provide
protection from lipid peroxidation propagated by
Figure 3 Concentration of serum hydrogen peroxide (microH2O2/ml) in the whole group (n = 10).
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xanthine oxidase/hypoxanthine in artificial systems
[28] and that persistent hypoalbuminemia in hemodia-
lysis patients is associated with peroxidation of ery-
throcyte membranes [29].M o r e o v e r ,a l b u m i ni st h e
major extracellular source of reduced sulfhydryl groups
(thiols), which are avid scavengers of reactive oxygen
and nitrogen species; in this way albumin influences
the redox balance [30,31].
The main limitations of this pilot study are its small
size and the possibility that the difference in ultrafiltra-
tion rates between the study periods may have affected
the validity of the results for both haemodynamics and
inflammation.
Conclusions
We have previously shown that systematic infusions of
20% albumin and 4% gelatin during hemodialysis ses-
sions improve hemodynamic parameters and the ultrafil-
tration rate in most hypotension-prone dialysis patients
unresponsive to usual preventive measures [9]. We
observed a parallel improvement in microinflammatory
status, which might be related to the decrease in both
ischemia-reperfusion of noble organs and oxidative
stress. Hyperoncotic 20% albumin was found to have
more potent anti-inflammatory and anti-oxidative prop-
erties than 4% gelatin.
Further well-designed controlled trials with a sufficient
number of patients are needed to confirm the efficacy of
hyperoncotic 20% albumin and 4% gelatin in hypoten-
sion-prone dialysis patients.
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